IBM’s $12.5 Billion AI Pipeline Tests Whether Software Can Salvage a Mainframe Wreck
Published on 07/27/2026 at 02:54 | Redaktion boerse-global.de
The numbers tell a story of two companies wearing the same nameplate. IBM’s software division posted a 5 percent revenue gain in the second quarter, with Red Hat surging 11 percent and data products jumping 18 percent. The cumulative generative AI order book has swelled to $12.5 billion. Yet the stock closed Friday at €188.38 — just 7.56 percent above its 52-week low of €175.14, hit on July 23 after the worst monthly slide in recent corporate memory.
The disconnect stems from a single, brutal fact: the mainframe business imploded. IBM Z revenue collapsed 42 percent in the quarter, dragging overall infrastructure sales down 7 percent to $3.84 billion. The company blamed the end of the z17 product cycle and a global memory-chip shortage that forced customers to prioritize servers and storage over legacy systems. The damage was severe enough that IBM slashed its full-year guidance from “more than 5 percent” constant-currency growth to a range of 4 to 5 percent.
Management has spent the days since the earnings release on a full-court press. CFO Jim Kavanaugh told Yahoo Finance there is no evidence customers are abandoning mainframes, insisting the key indicators point to what could be a record cycle compared with prior programs. CEO Arvind Krishna followed up in a CNBC interview on July 23, pushing back against fears that AI coding tools and competitors will erode IBM’s software business.
The reassurances were warranted. On the day of the initial profit warning, shares tumbled 25.2 percent to $217.07 — the largest single-day loss in the company’s 115-year history, with trading volume surging 551 percent above the three-month average. Adjusted earnings per share of $2.93 missed the $2.97 consensus, while revenue of $17.16 billion fell short of the $17.58 billion estimate. Net income dropped to $2.17 billion.
Should investors sell immediately? Or is it worth buying IBM?
Yet beneath the headline carnage, the numbers hint at overreaction. The relative strength index sits at 35.5, just above the threshold that typically marks oversold territory. The stock has already recovered more than 7 percent from its yearly low in just two trading sessions. At roughly 20 percent below the analyst price target of $231.06, the discount appears to reflect panic over a hardware cycle rather than a structural breakdown of the business model.
The software division’s resilience is the key variable. Revenue hit $7.76 billion in the quarter, with the consulting arm holding steady at $5.33 billion. Roughly 80 percent of software revenue is recurring, providing a buffer that the market may have initially overlooked. IBM is sticking with its free-cash-flow guidance of a $1 billion year-over-year improvement, and the company raised its quarterly dividend for the 30th consecutive time to $1.69 — a signal of financial discipline that carries weight during a downturn.
Analyst reactions remain split. Susquehanna’s James Friedman slashed his price target from $303 to $225 but kept a Neutral rating. Morgan Stanley, by contrast, raised its target by roughly 10 percent after the initial warning but before the full earnings release. Stifel’s David Grossman sees near-term sideways trading with a slight downward bias, citing limited visibility into coming quarters and seasonal headwinds.
IBM at a turning point? This analysis reveals what investors need to know now.
The near-term test is whether €175.14 holds as a floor. If it does, the July sell-off may prove to have been an overreaction to a cyclical hardware trough rather than the start of a longer decline. The real question is whether deferred large-scale orders close in the coming months and whether Red Hat and the watsonx software suite can continue to offset the infrastructure drag. The $12.5 billion AI order book suggests enterprise customers are still buying into IBM’s vision — but the mainframe cycle will have to turn before the stock can fully recover.
Ad
IBM Stock: New Analysis - 27 July
Fresh IBM information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
